scispace - formally typeset
G

Gideon Koren

Researcher at Ariel University

Publications -  2007
Citations -  88165

Gideon Koren is an academic researcher from Ariel University. The author has contributed to research in topics: Pregnancy & Population. The author has an hindex of 129, co-authored 1994 publications receiving 81718 citations. Previous affiliations of Gideon Koren include McGill University Health Centre & University of Western Ontario.

Papers
More filters
Journal ArticleDOI

Maternal and neonatal characteristics following exposure to cocaine in Toronto.

TL;DR: It is concluded that gestational exposure to cocaine, ascertained by a sensitive biologic marker, is associated with substantial perinatal risks.
Journal ArticleDOI

Heavy in utero ethanol exposure is associated with the use of other drugs of abuse in a high-risk population

TL;DR: In this paper, the association between drugs of abuse and concurrent use of ethanol in pregnancy was investigated and a 15.5% positive rate for intrauterine ethanol exposure was detected.
Journal ArticleDOI

Fetal and Neonatal Outcomes in Women Reporting Ingestion of Licorice (Glycyrrhiza uralensis) during Pregnancy

TL;DR: The present study suggests that licorice is not a major teratogen, however, whetherLicorice may increase the risk of stillbirths requires careful consideration in further studies with a larger sample size.
Journal Article

Maternal cocaine use during breastfeeding.

TL;DR: There is no reason for mothers who previously abused cocaine to avoid breastfeeding and attempts should be made to estimate maternal commitment to breastfeeding and discontinuation of cocaine use, and to offer addiction counseling to mitigate the potential risks of infant cocaine exposure.
Journal ArticleDOI

Life-threatening adverse events following therapeutic opioid administration in adults: is pharmacogenetic analysis useful?

TL;DR: Pharmacogenetic analysis, together with clinical history, has the potential to provide mechanistic insight into severe respiratory depressive events in patients who receive opioids at therapeutic doses.